Dronedarone: the Hope and the Hype by Manolis, Antonis S
21 
 
EDITORIAL  
 
Dronedarone: the Hope and the Hype 
 
Antonis S. Manolis, MD 
Evagelismos General Hospital of Athens, Athens, Greece 
 
Atrial fibrillation (AF) is the commonest cardiac 
arrhythmia afflicting ~1% of the total population in an 
age-dependent manner with 2.3% of individuals older 
than 40 years of age, or 5.9% of people older than 65.1 
Approximately 70% of persons with AF are between 65 
and 85 years of age. Patients with AF experience 
significantly higher mortality rates than patients without 
AF; adjusted relative mortality risk has been found 
approximately 20% higher in patients with AF in all age-
sex strata during each of the 3 years studied (P < 0.05).2 
One sixth of all strokes are attributable to AF and the 
percentage of strokes due to AF increases dramatically 
with age; of course the risk of stroke is significantly 
decreased with anticoagulation therapy by 60-70%, but 
this has its own inherent problems. Unfortunately, the use 
of antiarrhythmic drugs (AADs) employed thus far to 
maintain sinus rhythm is severely problematic with 
treatment being occasionally worse than the disease. 
Nevertheless, the goal is still to maintain sinus rhythm, 
since teleologically this is the optimal rhythm man is born 
and should live with, but the means to effect and sustain 
this, have inherent potentially prohibitive risks, as shown 
in the AFFIRM, RACE and other trials.3-5 However, even 
in the AFFIRM trial, which showed that AADs may be 
associated with increased mortality, overall maintenance 
of sinus rhythm (with or without AADs) was associated 
with improved survival compared with persistent AF. 
This observation supports the long-recognized mortality 
risk associated with AF,2 and hence the continued quest 
for development of new and safer antiarrhythmic agents 
and methods to maintain sinus rhythm. In this endeavor, 
newer pharmacological agents have recently emerged but 
not yet fulfilled this expectation. Among them, 
dronedarone, a modified molecule of amiodarone devoid 
of the iodine moiety, was heralded as the agent with the 
new hope.6  
In the initial studies employing the new drug 
(EURIDIS & ADONIS),7 dronedarone was significantly 
more effective than placebo in maintaining sinus rhythm 
in patients with paroxysmal AF (Table 1). Even, in 
patients with persistent or permanent AF, the new drug 
was reported to have favorable effects.8,9  However, when 
compared with amiodarone in patients with persistent AF 
(DIONYSOS study), dronedarone was less effective than 
amiodarone in decreasing AF recurrence, but the authors 
claimed that the new drug had a better safety profile, 10  
but the follow-up was limited to a median treatment 
duration of 7 months. The first worrisome outcome from 
this new AAD came from the ANDROMEDA trial,11 
which was terminated early because of a higher rate of 
death with dronedarone. This study was conducted in 
patients with symptomatic congestive heart failure, a left 
ventricular ejection fraction of <35%, and recent 
hospitalization with new or worsening heart failure.  
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Table 1. Dronedarone Studies 
 
Study No. of 
Patients 
Study 
Population 
Primary 
Endpoint 
Follow-
up 
Results 
DAFNE 199 Patients with 
persistent AF 
scheduled for 
cardioversion 
Time to AF 
relapse 
6 mos Median time to first AF recurrence: 5.3 days 
in the placebo group, & 60 days in the 
dronedarone 800 mg group (relative risk 
reduction 55%; P=0.001)  
EURIDIS 
/ADONIS 
1237 (828 
dronedarone / 409 
placebo) 
Patients with 
paroxysmal 
AF 
Time to AF 
recurrence 
12 mos Median times to AF recurrence: 41 days in 
placebo group & 96 days in dronedarone 
group (P= 0.01) (European trial); respective 
durations in the non-European trial: 59 & 158 
days (P= 0.002)  
ERATO 174 (85 
dronedarone / 89 
placebo) 
Patients with 
permanent AF 
Mean ventricular rate 
on day 14 (by Holter) 
6 mos Reduction of 11.7 bpm (P <0.0001) sustained 
at 6 months 
ANDROMEDA 627 (310 
dronedarone / 317 
placebo)  
Patients with 
HF (NYHA 
III/IV), LVEF 
<35% 
Death from any 
cause or 
hospitalization for 
heart failure 
2 mos 25 deaths in the dronedarone group 
(8.1%) & 12 in the placebo group 
(3.8%) (hazard ratio-HR, 2.13; P = 0.03). 
ATHENA 4628 (2301 
dronedarone / 
2327 placebo) 
Patients with 
paroxysmal or 
persistent AF 
or flutter 
first hospitaliza-tion 
due to CV events or 
death 
21 mos 24% reduction in death from all causes or 
first hospitalization for a CV event  
DIONYSOS 504 (249 
dronedarone / 255 
amiodarone) 
Patients with 
persistent AF 
AF recurrence 7 mos AF recurrence was higher with 
dronedarone compared with amiodarone 
(63.5 vs 42.0%) (HR 1.59; P<0.0001) 
PALLAS 3149 (1572 
dronedarone / 
1577 placebo) 
Patients with 
permanent 
AF 
Stroke, MI, systemic 
embolism, or CV 
death or unplanned 
hospitalization or 
death 
3.5 mos 16 (1%) deaths in the drug vs 7 (0.4%) in the 
placebo group. CV death, MI, stroke or 
systemic embolism in 32 (2%) vs 14 (0.9%) 
respectively (hazard ratio 2.3; p=0.009) 
 
AF = atrial fibrillation; CV = cardiovascular; HF = heart failure; HR = hazard ratio; MI = myocardial infarction; mos = months; NYHA 
= New York Heart Association  
 
 
There followed ATHENA, a prospective, double-
blind study,12 assessing morbidity and mortality rates in 
4,628 patients with AF or atrial flutter and at least one 
other cardiovascular risk factor. This study excluded 
patients with decompensated heart failure. It showed that 
dronedarone, added to standard therapy, significantly 
reduced the risk of a first cardiovascular hospitalization 
or death by 24% in patients with AF or atrial flutter.  
Although, with the results of the ATHENA trial, it 
seemed that a small niche was established for 
dronedarone for patients with paroxysmal or persistent 
AF or flutter, for prevention of AF recurrences, or even 
reduction of hospitalizations due to cardiovascular events, 
at least before resorting to amiodarone, as long as they 
had no symptoms of congestive heart failure or low 
ejection fraction, there followed shortly the results of the 
PALLAS trial, which cast serious doubts about the 
overall safety of this agent.13,14 With regards to safety of 
the drug, even before this latter trial, it should be noted 
that the adverse events occurred significantly more 
frequently with dronedarone than with placebo and 
included bradycardia, QT-interval prolongation, diarrhea, 
nausea, rash, and an increase in the serum creatinine 
level. In patients of the ATHENA trial, no significant 
increase in the rates of thyroid or pulmonary disorders 
was seen with dronedarone, however, as the authors 
noted, the mean follow-up for patients in the trial was 
only 21 months and many patients treated with 
amiodarone have such side effects (especially pulmonary 
fibrosis) later than 2 years after initiating therapy. 
Furthermore, a major clue for limited tolerance of the 
drug in this trial was the very high rate of premature 
discontinuation of the study drug reaching at 30.2% in the 
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dronedarone group. Subsequently, alarming news arrived 
about the potential liver toxicity of the drug from an FDA 
drug safety communication. In January 2011, the FDA 
warned “healthcare professionals and patients about cases 
of rare, but severe liver injury, including two cases of 
acute liver failure leading to liver transplant in patients 
treated with the heart medication dronedarone (Multaq)” 
(http://www.fda.gov/drugs/drugsafety/ucm240011.htm).15  
 
 The Permanent Atrial fibriLLAtion Outcome Study 
Using Dronedarone on Top of Standard Therapy 
(PALLAS) study, sponsored by the drug maker, was 
being conducted to assess the potential clinical benefit of 
dronedarone in patients over 65 years of age with 
permanent AF. PALLAS was launched in July 2010 and 
was designed to enroll 10,800 patients, with an estimated 
completion date of August 2013, but was stopped 
prematurely in July 2011 due to doubling of the mortality 
rate in this cohort  
(http://www.theheart.org/article/1251405.do).13,14 Only 3149 
patients had been enrolled at the time the study was 
stopped. As of June 30, 2011, 16 (1%) patients had died 
in the drug group compared to 7 (0.4%) patients dying in 
the placebo group. Cardiovascular death, myocardial 
infarction, stroke or systemic embolism had occurred in 
32 (2%) patients receiving the drug vs 14 (0.9%) among 
those receiving placebo (hazard ratio 2.3; p=0.009). On 
July 21, 2011, the FDA issued a warning that “healthcare 
professionals should not prescribe Multaq to patients with 
permanent atrial fibrillation”  
(http://www.fda.gov/Drugs/DrugSafety/ucm264059.htm).14  
 Thus, based on all these developments regarding this 
new agent, it seems that there may only remain a possible 
indication of this drug in patients with paroxysmal or 
persistent AF with preserved left ventricular function and 
no symptoms or signs of heart failure, while it is 
contraindicated in patients with permanent AF, regardless 
of the left ventricular function status. However, as post-
drug surveillance has already revealed worrisome 
problems with potential severe liver toxicity, taken 
altogether, it seems prudent to remain very circumspect in 
prescribing this medication in any patient, until further 
long-term data are available. It is also apparent that 
regulatory authorities have been a bit hasty, to say the 
least, with regards to their endorsement of this agent 
before all information had become available. It also 
remains inexplicable why the drugmaker and the involved 
investigators ever thought that the drug would have an 
indication in patients with permanent AF; nevertheless 
their action provided important negative information that 
will prevent future problems lest some physicians would 
have proceeded to prescribe this medication in such a 
high-risk patient group.  
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